秋水仙碱抑制G422胶质瘤生长的实验研究
|
摘要
目的:探讨运用MTT法测定秋水仙碱在体外是否具有抑制G422胶质瘤细胞生长增殖的作用;通过建立小鼠皮下胶质瘤模型,采用间质内注射不同剂量的秋水仙碱,观察是否能延长各实验组小鼠的生存周期和延缓肿瘤的生长。
方法:实验一设定6个秋水仙碱检测浓度,分别为0.03ug/mL、0.06ug/mL、0.12ug/mL、0.25ug/mL、0.5ug/mL、1ug/mL。采用MTT法测定经小鼠体内传代的G422胶质瘤细胞标本对以上6种不同浓度秋水仙碱的体外敏感性。
实验二建立小鼠皮下胶质瘤模型,将接种G422的小鼠随机分成4组,其中3组按秋水仙碱0.5、0.05、0.005mg/kg·d分为高、中、低实验组,另1组为生理盐水对照组,各组20只小鼠,分于接种G422后的第2d(即48h)、5d在原接种G422的局部皮下注射0.1ml药物,共2次。
结果:1.MTT法实验结果显示:不同浓度的秋水仙碱对G422胶质瘤细胞株的生长均有一定的抑制作用,其抑制率分别是0.03ug/mL组(36.41±4.16)%、0.06ug/mL组(51.33±5.30)%、0.12ug/mL组(65.47±2.77)%、0.25ug/mL组(70.54±2.42)%、0.5ug/mL组(75.38±1.10)%、1ug/mL组(77.37±2.25)%。随着药物浓度增大,瘤细胞生长抑制率呈增高的趋势。
2.皮下间质内化疗结果显示:秋水仙碱治疗组平均生存期均有延长,分别为44.28±1.07、43.79±1.64、43.09±1.39天;对照组的平均生存期为28.28±1.77天。多个样本均数的比较经方差分析,P＜0.01,各实验组荷瘤鼠生存期不同或不全相同。
结论:1.秋水仙碱在体外具有抑制G422胶质瘤细胞生长的作用,在0.03～1ug/mL浓度范围内,瘤细胞的生长抑制率随药物浓度的增大而增高。
2.秋水仙碱间质内化疗可以显着提高G422荷瘤鼠的生存周期和延缓肿瘤的生长。
3.秋水仙碱有可能成为一种新的抗胶质瘤的化疗药物。
Objective To evaluate the sensitivity of colchicine to the G422 glioma cell in vitro with colorimetric MTT assay.To inject different dosage of colchicine into mice with the G422 glioma and to observe whether this can prolong mice's life periods.
Methods Experiment one:In vitro,sensitivities of 6 different concentrations of colchicine were determined by MTT method in G422 glioma which spread generation in the small mice body,which 6 kinds of concentration respectively are 0.03ug/mL、0.06ug/mL、0.12ug/mL、0.25ug/mL、0.5ug/mL、1ug/mL.The G422 glioma cells were plated in 96-well tissue culture plates and incubated for 48h with colchicine. Experiment two:To establish 80 mices subcutaneous glioma model,these will be inoculated with G422 glioma were randomly divided into 4 groups.According to colchicine 0.5、0.05、0.005 mg/kg·d,3 groups of 4 are divided into high、medium and low experimental group,and the other one group is the saline control group.20 mices in each group,sub-in after G422 inoculation 2d(equivalent to 48h)、5d,will be injected 0.1ml of drugs at the original inoculation G422 subcutaneous,a total of 2 times.
Results 1.The growth of the G422 glioma cell can be restrained by 6 different concentrations of colchicine,and its inhibition rate are separately 0.03ug/ml Group (36.41±4.16)%,0.06ug/ml Group(51.33±5.30)%,0.12ug/ml Group(65.47±2.77)%,0.25ug/ml Group(70.54±2.42)%,0.5ug/ml Group(75.38±1.10)%,1ug/ml Group(77.37±2.25)%.The rate of restraining growth of tumour cell increased with the concentrations of medicine.2.By colchicine treatment,tumor-bearing mices have extended and the average survival time were 44.28±1.07,43.79±1.64,43.09±1.39 days;the control group the average survival time was 28.28±1.77 days.More than the number of samples are compared by analysis of variance,P＜0.01.
Conclusions 1.The growth of the G422 glioma cell in vitro can be restrained by colchicine.In the 0.03-1ug/mL density scope,the growth suppression rate of the G422 glioma cell increases along with the medicine density advances.
2.Chemotherapy of colchicine can significantly improve tumor-bearing with G422 mice's survival time and postpone tumor growth..
3.The colchicine has the possibility to become one kind of new chemotherapy medicine to anti-glioma.
方法:实验一设定6个秋水仙碱检测浓度,分别为0.03ug/mL、0.06ug/mL、0.12ug/mL、0.25ug/mL、0.5ug/mL、1ug/mL。采用MTT法测定经小鼠体内传代的G422胶质瘤细胞标本对以上6种不同浓度秋水仙碱的体外敏感性。
实验二建立小鼠皮下胶质瘤模型,将接种G422的小鼠随机分成4组,其中3组按秋水仙碱0.5、0.05、0.005mg/kg·d分为高、中、低实验组,另1组为生理盐水对照组,各组20只小鼠,分于接种G422后的第2d(即48h)、5d在原接种G422的局部皮下注射0.1ml药物,共2次。
结果:1.MTT法实验结果显示:不同浓度的秋水仙碱对G422胶质瘤细胞株的生长均有一定的抑制作用,其抑制率分别是0.03ug/mL组(36.41±4.16)%、0.06ug/mL组(51.33±5.30)%、0.12ug/mL组(65.47±2.77)%、0.25ug/mL组(70.54±2.42)%、0.5ug/mL组(75.38±1.10)%、1ug/mL组(77.37±2.25)%。随着药物浓度增大,瘤细胞生长抑制率呈增高的趋势。
2.皮下间质内化疗结果显示:秋水仙碱治疗组平均生存期均有延长,分别为44.28±1.07、43.79±1.64、43.09±1.39天;对照组的平均生存期为28.28±1.77天。多个样本均数的比较经方差分析,P＜0.01,各实验组荷瘤鼠生存期不同或不全相同。
结论:1.秋水仙碱在体外具有抑制G422胶质瘤细胞生长的作用,在0.03～1ug/mL浓度范围内,瘤细胞的生长抑制率随药物浓度的增大而增高。
2.秋水仙碱间质内化疗可以显着提高G422荷瘤鼠的生存周期和延缓肿瘤的生长。
3.秋水仙碱有可能成为一种新的抗胶质瘤的化疗药物。
Objective To evaluate the sensitivity of colchicine to the G422 glioma cell in vitro with colorimetric MTT assay.To inject different dosage of colchicine into mice with the G422 glioma and to observe whether this can prolong mice's life periods.
Methods Experiment one:In vitro,sensitivities of 6 different concentrations of colchicine were determined by MTT method in G422 glioma which spread generation in the small mice body,which 6 kinds of concentration respectively are 0.03ug/mL、0.06ug/mL、0.12ug/mL、0.25ug/mL、0.5ug/mL、1ug/mL.The G422 glioma cells were plated in 96-well tissue culture plates and incubated for 48h with colchicine. Experiment two:To establish 80 mices subcutaneous glioma model,these will be inoculated with G422 glioma were randomly divided into 4 groups.According to colchicine 0.5、0.05、0.005 mg/kg·d,3 groups of 4 are divided into high、medium and low experimental group,and the other one group is the saline control group.20 mices in each group,sub-in after G422 inoculation 2d(equivalent to 48h)、5d,will be injected 0.1ml of drugs at the original inoculation G422 subcutaneous,a total of 2 times.
Results 1.The growth of the G422 glioma cell can be restrained by 6 different concentrations of colchicine,and its inhibition rate are separately 0.03ug/ml Group (36.41±4.16)%,0.06ug/ml Group(51.33±5.30)%,0.12ug/ml Group(65.47±2.77)%,0.25ug/ml Group(70.54±2.42)%,0.5ug/ml Group(75.38±1.10)%,1ug/ml Group(77.37±2.25)%.The rate of restraining growth of tumour cell increased with the concentrations of medicine.2.By colchicine treatment,tumor-bearing mices have extended and the average survival time were 44.28±1.07,43.79±1.64,43.09±1.39 days;the control group the average survival time was 28.28±1.77 days.More than the number of samples are compared by analysis of variance,P＜0.01.
Conclusions 1.The growth of the G422 glioma cell in vitro can be restrained by colchicine.In the 0.03-1ug/mL density scope,the growth suppression rate of the G422 glioma cell increases along with the medicine density advances.
2.Chemotherapy of colchicine can significantly improve tumor-bearing with G422 mice's survival time and postpone tumor growth..
3.The colchicine has the possibility to become one kind of new chemotherapy medicine to anti-glioma.
引文
1.吴承远,刘玉光主编.临床神经外科学[M].第二版.北京:人民卫生出版社,2007:170-178
2.蒋传路,江涛,李永利,等.胶质瘤的侵袭性与手术策略[J].中华神经外科杂志,2004,20:510-512
3.陈忠平,张俊平.恶性脑肿瘤化疗新动态:分子靶向治疗[J].中国神经肿瘤杂志,2007,3:1-5
4.刘福生,金贵善,历俊华,等.树突状细胞与反义TGF-β1基因修饰的胶质瘤细胞融合疫苗治疗脑胶质瘤的实验研究[J].中华神经外科杂志,2006,22:47-50
5.黄强.神经干细胞和脑肿瘤干细胞相关性研究[J].中国微侵袭神经外科杂志,2006,11(8):377-379
6.胡韶山,王齐,岳武,等.光动力辅助显微手术治疗脑胶质瘤[J].中华神经外科杂志,2007,20:30-32
7.刘伟国.胶质瘤综合治疗进展[J].实用肿瘤杂志,2004,19(6):462-464
8.漆松涛,邱炳辉.手术切除联合间质内缓释化疗治疗复发性脑胶质瘤[J].中华肿瘤杂志,2004,26(1):58-61
9.Hoehboerg FH,Pruitt A.Assumptions in the radiotherapy of glioblastoma[J].Neurology,1998,30(9):907-911
10.Grossman SA,Reinhard C,Colvin Om,et al.The intracerebral distribution of BCUN delivered by surgically implanted biodegradable polymerse[J].Neurosurgery,2000,76(4):640-647
11.Yang MB,Refael JB,Brem H.controlled delivered of(1,3-bis(2,3-chlowethy)) rutraurea from ehhylene-vinly acetate copolymerse.Cancer Res,1999,49(18):5103-5107
12.Thompson RC,Brem H.Treatment ofgliomas using polymer-drug delivery[M].From:Berger MS and Wilson CB(eds)W.B.The gliomas.Sannders company,Toronto,2000:555-563
13.Sipos EP,Tyler B,Piantadosi S,et al.Optimimizing interstitial delivery of BUCN from controlled release polymers for the treatment of brain tumors[J].Cancer chemotherapy pharmacol,2003,39:383-389
14.马晓东,章文斌,周定标.BCNU缓释微球稳定性的影响因素[J].临床神经外科杂志,2007.4(4):148-150
15.Ben-Chetrit E,Levy M.Colchicine:1998 update[J].Semin Arthritis Rheum.1998,28(1):48-59
16.Zhang SX,Feng J,Kuo SC,etal.Antitumor agents.199.Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis[J].J Med Chem,2000,43(2):167-176
17.李晖,柴煊,范亚军综述 李灵芝审校.合成微管微丝抑制药的研究进展[J].武警医学,2007,18(10):781-783
18.曹静,赵志华,李道明.MTT法测定食管癌细胞株化疗药物敏感性[J].肿瘤基础与临床,2006,19(3):187-190
19.石松魁.乳腺癌术前辅助化疗后原发肿瘤临床改变与预后[J].中国肿瘤临床,1992,19(4):276-280
20.李耀武综述,周有骏,朱驹审校.作用于微管的抗肿瘤药物研究进展[J].国外医学药学分册,2005,32(1):1-5
21.Brossi A,Yeh HJC,Chrzanowska M,et al..Colchicine and its analogues:recent findings[J].Med Res Rev,1998,8(1):77-86
22.Wang Bin,Pan Xian dao,Lu Hong yan,et al.Synthesis and antitumor activity of Nitrogen-based thiocolchicine derivatives[J].药学学报,2006,41(11):1057-1063
23.Fitzgerald PH,Bbrehault LA.Depression of DNA synthesis and mitotic index by colchicine in cultured human lymphocytes.Exp Cell Res,1990,59(1):27-31
24.李方成,郭希高,陶宗玉,等.秋水仙素对C6胶质瘤细胞葡萄糖摄取的影响.中华实验外科杂志,2006,20(2):141-142
25.于朝春,周范民,王宇倩等.脑胶质瘤的化疗敏感性研究.中华神经医学杂志,2005,(47):686-691
26.黄庆玖,杨天明,李耀华.苯乙酸钠抑制脑胶质瘤的实验研究.临床神经病学杂志,2007,15(1):5-9
27.石新东,赵洪洋,冯军,等.立体定向法建立大鼠C6脑胶质瘤模型.中华神经医学杂志,2007.6(2):123-126
28.陈炳桓,邵文钊,徐庆中,等.实验性小鼠胶质瘤的诱发和G422胶质母细胞瘤瘤株的建立.北京医学,1981,3:15-18
29.CHENZhi-Gang,BroaddusWC,ZHU Cheng,et al.Current stams of gene therapy for gliomas[J].Acad J Sec Mil Med Univ,2004,25(1):96-101
30.高进喜综述,王守森、王如密审校.胶质瘤化疗进展[J].中国微侵袭神经外科杂志,2008,9(5):233-237
31.Haroun RI,Brem H.Local drug delivery[J].Curt Opin Oncol,2000,12(3):187-193
32.牟永告,陈忠平.脑恶性胶质瘤的局部治疗[J].中国微侵神经外科杂志,2003;8(8):379-381
33.王金环 李牧(综述),王守伦(审校).脑胶质瘤局部缓释化疗的研究进展[J].神经疾病与精神卫生,2007,1(4):59-60
34.刘金龙,陈硕朗,林佳平,等.胶质瘤显微手术切除加术中间质化疗的临床效果[J].中华显微外科杂志,2005,26(2):156-158
35.王树凯,保建基,徐国本,等.脑胶质瘤术中博莱霉素缓释化疗12例[J].郑州大学学报,2007,37(5):698-699
36.Voulgaris S,Partheni M,Karamouzis M,et al.Intratumoral doxorubicin in patients with malignant brain gliomas[J].Am-J-Clin-Onc,2002,25(1):60-64
37.于耀宇,马廉亭,秦尚振,等.脑胶质瘤术后间质化疗联合同步放疗的临床研究[J].中国临床神经外科杂志,2005,25:342-344
38.Sipos EP,Tyler B,Piantadosi S,et al.Optimizing interstitial dclivery of BCUN from controlled release trolymers for the treatment of brain tumors[J].Cancer chemother phammcol,2003,39:383-389
39.Walter KA,Cahan MA,Gur A,et al.Interstitial taxol delivery from a biodegradable polymer implant against experimental malignant glioma[J].Cancer Res 2004,54:2207-2212
40.Weingart JD,Thompson RC,Fylcr B,et al.Local delivery of the topoisomerase-1 inhibitor camptothecin sodium prolongs survival in the rat intracranlal 9L gliosarcoma model[J].Int J Cancer,2005,62:605-609
41.Tamargo Ⅲ,Sills AK,Reinhard CS,et al.Interstitial dexamet thasone deliver in the brain for the reduction of peritumoral edema[J].Neurosurg,2001,74:956-961
42.Tamargo RL,Myseros JS,Jonathan 1,et al.Interstitial chemotherapy of the 9L gliosarcoma:Controlled release polymers for drug delivery in the brain[J].Cancer Research.2003,53:329-333
43.Michafel Schmoeckel,Farah NK,Afzal Zaldi.et al.Orthotopic heart transplantation in a transgenicpig-to-primatemodel.Transplantation,2008,65(12):1570
44.Platt IT,et al.An ELISA assay for xenoreactive natural antibodies.2004,49:1000
45.周光华,董军,吴自成,等.替莫唑胺缓释剂胶质瘤问质内化疗的实验研究[J].中国微侵袭神经外科杂志,2008,13(10):455-459
1.陈忠平.胶质瘤治疗的困惑与思考[J].中华神经外科杂志,2008,24(4):310-311
2.Deorah S,Lynch CF,Sibenaller ZA,et al.Trends in brain cancer incidence and survival in the United States:Surveillance,Epidemiology,and End Results Program,1973 to 2001.NeurosurgFocus,2006,20(4):el
3.Schaller B.Usefulness of positron emission tomography in diagnosis and treatment follow-up of brain mmors.NeurobiolDis,2004,15:437448
4.蒋传路,江涛,李永利,等.胶质瘤的侵袭性与手术策略.中华神经外科杂志,2004,20:510-512
5.Levivier M,Massager N,Wikler D,et al.Use of stereotactic PET image in dosimetry planning of radiosurgery for brain tumors:clinical experience and proposed classification.J NuclMed,2004,45:1146-1154
6.陈忠平.脑胶质瘤的临床治疗方向[J].中华神经外科杂志,2007,23(2):81-83
7.陈忠平.重视脑胶质瘤的个体化综合治疗[J].广东医学,2005,26(9):1169-1171
8.李士其,周良辅,王知秋,等.脑干占位性病变的显微外科治疗再探讨[J].中国临床神经科学,2000,8:209-219
9.王忠诚.脑干占位病变及外科治疗[J].中华神经外科杂志,2004,20:99-100
10.段国升,朱诚主编.神经外科手术学[M].第二版人民军医出版社,2004
11.赵世光,藤雷,赵洪波,等.荧光引导鼠胶质瘤切除的实验研究[J].中华神经外科杂志,2006,22:30-32
12.王鹏,章翔,江新标,等.硼中子俘获疗法治疗小鼠颅内G422胶质细胞瘤[J].中华神经医学杂志,2007,6(9):892-895
13.胡韶山,王齐,岳武,等.光动力辅助显微手术治疗脑胶质瘤[J].中华神经外科杂志,2004,20:30-32
14.杨福义.~(125)I粒子瘤内放疗治疗胶质瘤术后远期疗效观察[J].黑龙江医药科学,2005,28(1).35-37
15.Barani IJ,Benedict SH,Lin PS.Neural stem cells:implications for the conventional radiotherapy of central nervous system malignancies.Int J Radiat Oncol Biol Phys,2007,68:324-333
16.朱玉德,季晓燕,黄强,等.人脑胶质瘤干细胞初步研究[J].中华神经外科杂志,2007,23:127-130
17.Stewart LA.Chemotherapy in adult high-grade glioma:a systematic review and meta-analysis of individual patient data from 12 randomised trials.Lancet,2002,359:1011-1018
18.Mutter N,Stupp R.Temozolomide:a milestone in neurooncology and beyond?[J].Expert Rev Anticancer Ther,2006,6(8):1187-1204
19.曾宪起,申长虹,浦佩玉,等.应用替莫唑胺对照司莫司丁治疗恶性胶质瘤的疗效观察[J].中华神经外科杂志,2006:22:204-207
20.Kokkinakis D M,Bocangel D B,Schold S C,et al.Thresholds of 06-alkylguanine-DNA alkyltrxansferase which confer significant resistance of human glial tumor xenografls to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide[J].Clin Cancer Res,2001,7(2):421-428
21.Parajuli P,Mathupala S,Mittal S,et al.Dendritic cell-based active specific immunotherapy for malignant glioma.Expert Opin Biol Ther,2007,7(4):439-448
22.CHEN Zhi-Gang,ZHU Cheng.Current status of gene therapy for gliomas[J].A cad J Sec MilMedUniv,2004,25(1):96-99
23.陈鹏,杨小锋,等.人脑胶质瘤基因治疗进展[J].浙江创伤外科,2004,9(1):68-70
24.Reynolds BA,Weiss S.Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system[J].Science,1992,255(5052):1707-1710
25.Panagiotakos G,Tabar V.Brain tumor stem cells[J].Curr Neurol Neurosci Rep,2007,7(3):215-220
26.Dirks PB.Brain tumor stem cells[J].Biol Blood Marrow Transplant,2005,11(2 Suppl 2):12-13
27.Nakano I,Komblum HI.Brain tumor stem cells[J].2006,59(4 Pt 2):54R-58R
28.Hanahan D,Weinberg RA.The hallmarks of cancer[J].Cell,2000,100(1):57-70
29.Recht L,Jang T,Savarese T,et al.Neural stem cells and neuro-oncolgy:quo vadis?[J].J Cell Biochem,2003,88(1):11-19
30.Berger F,Gay E,Pelletier L.et al.Development of gliomas:potential role of asymmetrical cell division of neural stem cells[J].Lancet Oncol,2004,5(8):511-514
31.Betschinger J,Mechtler K,Konblich JA.The Par complex directs asymmetric cell division by phosphorylating the cytoskeletal protein Lgl[J].Nature,2003,422(6929):326-330
32.周志华,易良,卞修武.胶质瘤干细胞研究进展[J].中华病理学杂志,2007,36:201-203
33.朱玉德,季晓燕,黄强,等.人脑胶质瘤干细胞初步研究[J].中华神经外科杂志,2007,23:127—130
34.毕长龙,方加胜,陈风华,等.CD133胶质瘤干细胞化疗耐受机制分析[J].中南大学学报(医学版),2007,32:568-573
35.陈苏峰 综述 钟竑 审校.肿瘤干细胞研究进展[J].上海交通大学学报(医学版),2006,26(5):548-552
2.蒋传路,江涛,李永利,等.胶质瘤的侵袭性与手术策略[J].中华神经外科杂志,2004,20:510-512
3.陈忠平,张俊平.恶性脑肿瘤化疗新动态:分子靶向治疗[J].中国神经肿瘤杂志,2007,3:1-5
4.刘福生,金贵善,历俊华,等.树突状细胞与反义TGF-β1基因修饰的胶质瘤细胞融合疫苗治疗脑胶质瘤的实验研究[J].中华神经外科杂志,2006,22:47-50
5.黄强.神经干细胞和脑肿瘤干细胞相关性研究[J].中国微侵袭神经外科杂志,2006,11(8):377-379
6.胡韶山,王齐,岳武,等.光动力辅助显微手术治疗脑胶质瘤[J].中华神经外科杂志,2007,20:30-32
7.刘伟国.胶质瘤综合治疗进展[J].实用肿瘤杂志,2004,19(6):462-464
8.漆松涛,邱炳辉.手术切除联合间质内缓释化疗治疗复发性脑胶质瘤[J].中华肿瘤杂志,2004,26(1):58-61
9.Hoehboerg FH,Pruitt A.Assumptions in the radiotherapy of glioblastoma[J].Neurology,1998,30(9):907-911
10.Grossman SA,Reinhard C,Colvin Om,et al.The intracerebral distribution of BCUN delivered by surgically implanted biodegradable polymerse[J].Neurosurgery,2000,76(4):640-647
11.Yang MB,Refael JB,Brem H.controlled delivered of(1,3-bis(2,3-chlowethy)) rutraurea from ehhylene-vinly acetate copolymerse.Cancer Res,1999,49(18):5103-5107
12.Thompson RC,Brem H.Treatment ofgliomas using polymer-drug delivery[M].From:Berger MS and Wilson CB(eds)W.B.The gliomas.Sannders company,Toronto,2000:555-563
13.Sipos EP,Tyler B,Piantadosi S,et al.Optimimizing interstitial delivery of BUCN from controlled release polymers for the treatment of brain tumors[J].Cancer chemotherapy pharmacol,2003,39:383-389
14.马晓东,章文斌,周定标.BCNU缓释微球稳定性的影响因素[J].临床神经外科杂志,2007.4(4):148-150
15.Ben-Chetrit E,Levy M.Colchicine:1998 update[J].Semin Arthritis Rheum.1998,28(1):48-59
16.Zhang SX,Feng J,Kuo SC,etal.Antitumor agents.199.Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis[J].J Med Chem,2000,43(2):167-176
17.李晖,柴煊,范亚军综述 李灵芝审校.合成微管微丝抑制药的研究进展[J].武警医学,2007,18(10):781-783
18.曹静,赵志华,李道明.MTT法测定食管癌细胞株化疗药物敏感性[J].肿瘤基础与临床,2006,19(3):187-190
19.石松魁.乳腺癌术前辅助化疗后原发肿瘤临床改变与预后[J].中国肿瘤临床,1992,19(4):276-280
20.李耀武综述,周有骏,朱驹审校.作用于微管的抗肿瘤药物研究进展[J].国外医学药学分册,2005,32(1):1-5
21.Brossi A,Yeh HJC,Chrzanowska M,et al..Colchicine and its analogues:recent findings[J].Med Res Rev,1998,8(1):77-86
22.Wang Bin,Pan Xian dao,Lu Hong yan,et al.Synthesis and antitumor activity of Nitrogen-based thiocolchicine derivatives[J].药学学报,2006,41(11):1057-1063
23.Fitzgerald PH,Bbrehault LA.Depression of DNA synthesis and mitotic index by colchicine in cultured human lymphocytes.Exp Cell Res,1990,59(1):27-31
24.李方成,郭希高,陶宗玉,等.秋水仙素对C6胶质瘤细胞葡萄糖摄取的影响.中华实验外科杂志,2006,20(2):141-142
25.于朝春,周范民,王宇倩等.脑胶质瘤的化疗敏感性研究.中华神经医学杂志,2005,(47):686-691
26.黄庆玖,杨天明,李耀华.苯乙酸钠抑制脑胶质瘤的实验研究.临床神经病学杂志,2007,15(1):5-9
27.石新东,赵洪洋,冯军,等.立体定向法建立大鼠C6脑胶质瘤模型.中华神经医学杂志,2007.6(2):123-126
28.陈炳桓,邵文钊,徐庆中,等.实验性小鼠胶质瘤的诱发和G422胶质母细胞瘤瘤株的建立.北京医学,1981,3:15-18
29.CHENZhi-Gang,BroaddusWC,ZHU Cheng,et al.Current stams of gene therapy for gliomas[J].Acad J Sec Mil Med Univ,2004,25(1):96-101
30.高进喜综述,王守森、王如密审校.胶质瘤化疗进展[J].中国微侵袭神经外科杂志,2008,9(5):233-237
31.Haroun RI,Brem H.Local drug delivery[J].Curt Opin Oncol,2000,12(3):187-193
32.牟永告,陈忠平.脑恶性胶质瘤的局部治疗[J].中国微侵神经外科杂志,2003;8(8):379-381
33.王金环 李牧(综述),王守伦(审校).脑胶质瘤局部缓释化疗的研究进展[J].神经疾病与精神卫生,2007,1(4):59-60
34.刘金龙,陈硕朗,林佳平,等.胶质瘤显微手术切除加术中间质化疗的临床效果[J].中华显微外科杂志,2005,26(2):156-158
35.王树凯,保建基,徐国本,等.脑胶质瘤术中博莱霉素缓释化疗12例[J].郑州大学学报,2007,37(5):698-699
36.Voulgaris S,Partheni M,Karamouzis M,et al.Intratumoral doxorubicin in patients with malignant brain gliomas[J].Am-J-Clin-Onc,2002,25(1):60-64
37.于耀宇,马廉亭,秦尚振,等.脑胶质瘤术后间质化疗联合同步放疗的临床研究[J].中国临床神经外科杂志,2005,25:342-344
38.Sipos EP,Tyler B,Piantadosi S,et al.Optimizing interstitial dclivery of BCUN from controlled release trolymers for the treatment of brain tumors[J].Cancer chemother phammcol,2003,39:383-389
39.Walter KA,Cahan MA,Gur A,et al.Interstitial taxol delivery from a biodegradable polymer implant against experimental malignant glioma[J].Cancer Res 2004,54:2207-2212
40.Weingart JD,Thompson RC,Fylcr B,et al.Local delivery of the topoisomerase-1 inhibitor camptothecin sodium prolongs survival in the rat intracranlal 9L gliosarcoma model[J].Int J Cancer,2005,62:605-609
41.Tamargo Ⅲ,Sills AK,Reinhard CS,et al.Interstitial dexamet thasone deliver in the brain for the reduction of peritumoral edema[J].Neurosurg,2001,74:956-961
42.Tamargo RL,Myseros JS,Jonathan 1,et al.Interstitial chemotherapy of the 9L gliosarcoma:Controlled release polymers for drug delivery in the brain[J].Cancer Research.2003,53:329-333
43.Michafel Schmoeckel,Farah NK,Afzal Zaldi.et al.Orthotopic heart transplantation in a transgenicpig-to-primatemodel.Transplantation,2008,65(12):1570
44.Platt IT,et al.An ELISA assay for xenoreactive natural antibodies.2004,49:1000
45.周光华,董军,吴自成,等.替莫唑胺缓释剂胶质瘤问质内化疗的实验研究[J].中国微侵袭神经外科杂志,2008,13(10):455-459
1.陈忠平.胶质瘤治疗的困惑与思考[J].中华神经外科杂志,2008,24(4):310-311
2.Deorah S,Lynch CF,Sibenaller ZA,et al.Trends in brain cancer incidence and survival in the United States:Surveillance,Epidemiology,and End Results Program,1973 to 2001.NeurosurgFocus,2006,20(4):el
3.Schaller B.Usefulness of positron emission tomography in diagnosis and treatment follow-up of brain mmors.NeurobiolDis,2004,15:437448
4.蒋传路,江涛,李永利,等.胶质瘤的侵袭性与手术策略.中华神经外科杂志,2004,20:510-512
5.Levivier M,Massager N,Wikler D,et al.Use of stereotactic PET image in dosimetry planning of radiosurgery for brain tumors:clinical experience and proposed classification.J NuclMed,2004,45:1146-1154
6.陈忠平.脑胶质瘤的临床治疗方向[J].中华神经外科杂志,2007,23(2):81-83
7.陈忠平.重视脑胶质瘤的个体化综合治疗[J].广东医学,2005,26(9):1169-1171
8.李士其,周良辅,王知秋,等.脑干占位性病变的显微外科治疗再探讨[J].中国临床神经科学,2000,8:209-219
9.王忠诚.脑干占位病变及外科治疗[J].中华神经外科杂志,2004,20:99-100
10.段国升,朱诚主编.神经外科手术学[M].第二版人民军医出版社,2004
11.赵世光,藤雷,赵洪波,等.荧光引导鼠胶质瘤切除的实验研究[J].中华神经外科杂志,2006,22:30-32
12.王鹏,章翔,江新标,等.硼中子俘获疗法治疗小鼠颅内G422胶质细胞瘤[J].中华神经医学杂志,2007,6(9):892-895
13.胡韶山,王齐,岳武,等.光动力辅助显微手术治疗脑胶质瘤[J].中华神经外科杂志,2004,20:30-32
14.杨福义.~(125)I粒子瘤内放疗治疗胶质瘤术后远期疗效观察[J].黑龙江医药科学,2005,28(1).35-37
15.Barani IJ,Benedict SH,Lin PS.Neural stem cells:implications for the conventional radiotherapy of central nervous system malignancies.Int J Radiat Oncol Biol Phys,2007,68:324-333
16.朱玉德,季晓燕,黄强,等.人脑胶质瘤干细胞初步研究[J].中华神经外科杂志,2007,23:127-130
17.Stewart LA.Chemotherapy in adult high-grade glioma:a systematic review and meta-analysis of individual patient data from 12 randomised trials.Lancet,2002,359:1011-1018
18.Mutter N,Stupp R.Temozolomide:a milestone in neurooncology and beyond?[J].Expert Rev Anticancer Ther,2006,6(8):1187-1204
19.曾宪起,申长虹,浦佩玉,等.应用替莫唑胺对照司莫司丁治疗恶性胶质瘤的疗效观察[J].中华神经外科杂志,2006:22:204-207
20.Kokkinakis D M,Bocangel D B,Schold S C,et al.Thresholds of 06-alkylguanine-DNA alkyltrxansferase which confer significant resistance of human glial tumor xenografls to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide[J].Clin Cancer Res,2001,7(2):421-428
21.Parajuli P,Mathupala S,Mittal S,et al.Dendritic cell-based active specific immunotherapy for malignant glioma.Expert Opin Biol Ther,2007,7(4):439-448
22.CHEN Zhi-Gang,ZHU Cheng.Current status of gene therapy for gliomas[J].A cad J Sec MilMedUniv,2004,25(1):96-99
23.陈鹏,杨小锋,等.人脑胶质瘤基因治疗进展[J].浙江创伤外科,2004,9(1):68-70
24.Reynolds BA,Weiss S.Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system[J].Science,1992,255(5052):1707-1710
25.Panagiotakos G,Tabar V.Brain tumor stem cells[J].Curr Neurol Neurosci Rep,2007,7(3):215-220
26.Dirks PB.Brain tumor stem cells[J].Biol Blood Marrow Transplant,2005,11(2 Suppl 2):12-13
27.Nakano I,Komblum HI.Brain tumor stem cells[J].2006,59(4 Pt 2):54R-58R
28.Hanahan D,Weinberg RA.The hallmarks of cancer[J].Cell,2000,100(1):57-70
29.Recht L,Jang T,Savarese T,et al.Neural stem cells and neuro-oncolgy:quo vadis?[J].J Cell Biochem,2003,88(1):11-19
30.Berger F,Gay E,Pelletier L.et al.Development of gliomas:potential role of asymmetrical cell division of neural stem cells[J].Lancet Oncol,2004,5(8):511-514
31.Betschinger J,Mechtler K,Konblich JA.The Par complex directs asymmetric cell division by phosphorylating the cytoskeletal protein Lgl[J].Nature,2003,422(6929):326-330
32.周志华,易良,卞修武.胶质瘤干细胞研究进展[J].中华病理学杂志,2007,36:201-203
33.朱玉德,季晓燕,黄强,等.人脑胶质瘤干细胞初步研究[J].中华神经外科杂志,2007,23:127—130
34.毕长龙,方加胜,陈风华,等.CD133胶质瘤干细胞化疗耐受机制分析[J].中南大学学报(医学版),2007,32:568-573
35.陈苏峰 综述 钟竑 审校.肿瘤干细胞研究进展[J].上海交通大学学报(医学版),2006,26(5):548-552